American Association for Cancer Research
15417786mcr190722-sup-225610_4_supp_5846165_pzpnxj.docx (29.03 kB)

Supplemental Materials and Methods from Capping Protein Regulator and Myosin 1 Linker 3 Is Required for Tumor Metastasis

Download (29.03 kB)
journal contribution
posted on 2023-04-03, 17:40 authored by Huan Wang, Chao Wang, Guang Peng, Doudou Yu, Xin-Gang Cui, Ying-Hao Sun, Xiaojing Ma

All Supplemental Materials and Methods


Natural Science Foundation of China

Shanghai Medical Guidance (Chinese and Western Medicine) Science and Technology

Clinical Discipline Project of Shanghai Pudong

National Natural Science Foundation of China

Program of Shanghai Academic/Technology Research Leader



Metastasis accounts for 90% of deaths caused by solid tumors, but the multitude of mechanisms underlying tumor metastasis remains poorly understood. CARMIL1 and 2 proteins are capping protein (CP) interactants and multidomain regulators of actin-based mobility. However, CARMIL3′s function has not been explored. Through bioinformatic metadata analysis, we find that high CARMIL3 expression correlates with poor survival of patients with breast and prostate cancer. Functional studies in murine and xenograft tumor models by targeted diminution of CARMIL3 expression or forced expression demonstrate that CARMIL3 is vitally important for tumor metastasis, especially for metastatic colonization. Consistent with a predominantly cell-intrinsic mode of action, CARMIL3 is also crucial for tumor cell migration and invasion in vitro. Coimmunoprecipitation coupled with mass spectrometric analyses identifies a group of CARMIL3-interacting proteins, including capping protein, that are involved in actin cytoskeletal organization, which is required for cell polarization and focal adhesion formation. Moreover, molecular pathway enrichment analysis reveals that lack of CARMIL3 leads to loss of cell adhesions and low CARMIL3 expression in breast cancer patient specimens is implicated in epithelial–mesenchymal transition. We also find that CARMIL3 sustains adherens junction between tumor cells. This is accomplished by CARMIL3 maintaining E-cadherin transcription downstream of HDACs through inhibiting ZEB2 protein level, also via protecting β-catenin from ubiquitination-mediated degradation initiated by the destruction complex. This study uncovers CARMIL3 as a novel and critical regulator of metastatic progression of cancers and suggests therapeutic potentials to target CARMIL3.

Usage metrics

    Molecular Cancer Research



    Ref. manager